hVIVO PLC (LON:HVO) said its vaccine for mosquito-borne diseases “warrants further development”.
The company made the assertion following the release of partial data from a phase I trial related to safety and humoral response (which relates to the drug’s potential to induce immunity).
The update on the hVIVO inoculation was released by the National Institutes of Health (NIH), which shared the new information to American Society of Tropical Medicine and Hygiene's annual conference in New Orleans.
"The presentation of these partial preliminary results by NIH at the conference is encouraging regarding safety and immunogenicity responses,” said chairman Trevor Phillips.
“We look forward to seeing the full data when the NIH completes the sample analyses in due course, at which point, a full assessment of the trial results will be possible".
The remaining primary and secondary results from the phase I study “will be evaluated once the full and final data are available”, said hVIVO.